Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector news 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

03/26/2012 | 11:50am US/Eastern

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Johnson & Johnson
React to this article
Latest news on JOHNSON & JOHNSON
11/25 JOHNSON & JOHNSON : Court revives Oregon suit over 'phantom recall' of Motrin
11/25 JOHNSON & JOHNSON : Appeals Court revives Oregon's lawsuit over 'phantom recall'..
11/25 GBCHealth & Global Health Council Announce Winners of Best Corporate Global H..
11/25 With U.S.-Cuba detente, a battle over trademarks looms
11/25 JOHNSON & JOHNSON : Announces $1.75 Million Donation to Save the Children to Sup..
11/24 JOHNSON & JOHNSON : Hutchinson Regional names Johnson new hospital CEO
11/23 GBCHealth & Global Health Council Announce Winners of Best Corporate Global H..
11/20 TAKEDA PHARMACEUTICAL : FDA approves a third drug for blood cancer multiple myel..
11/20 JOHNSON & JOHNSON : FDA approves Takeda drug for blood cancer multiple myeloma
11/19DJHorizon Pharma Withdraws Bid for Depomed
News chart
Full-screen chart
Income Statement Evolution
More Financials